國立成功大學 |
2023 |
Transpulmonary Expression of Exosomal microRNAs in Idiopathic and Congenital Heart Disease–Related Pulmonary Arterial Hypertension
|
Chang, W.-T.;Lee, W.-C.;Lin, Y.-W.;Shih, J.-Y.;Hong, C.-S.;Chen, Z.-C.;Chu, Chu C.-Y.;Hsu, C.-H. |
國立成功大學 |
2023 |
Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study
|
Chiu, Chiu C.-H.;Lin, M.-C.;Wei, Y.-F.;Chang, G.-C.;Su, W.-C.;Hsia, T.-C.;Su, J.;Wang, A.K.-F.;Jen, M.-H.;Puri, T.;Shih, J.-Y. |
國立成功大學 |
2023 |
Comparing Vitamin K Antagonists and Direct Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement: A Meta-Analysis
|
Lee, W.-C.;Shih, J.-Y.;Fang, H.-Y.;Wu, P.-J.;Fang, C.-Y.;Chen, H.-C.;Fang, Y.-N.;Chang, W.-T.;Chen, M.-C. |
臺大學術典藏 |
2022-09-20T07:56:57Z |
Effects of left atrial strain on functional capacity in chronic severe mitral regurgitation
|
LI-TAN YANG; Shih J.-Y.; Liu Y.-W.; Li Y.-H.; Tsai L.-M.; Luo C.-Y.; Tsai W.-C. |
臺大學術典藏 |
2022-09-20T07:56:56Z |
Predictive value of left atrial deformation on prognosis in severe primary mitral regurgitation
|
LI-TAN YANG; Liu Y.-W.; Shih J.-Y.; Li Y.-H.; Tsai L.-M.; Luo C.-Y.; Tsai W.-C. |
臺大學術典藏 |
2022-09-20T06:48:44Z |
In-hospital implementation of evidence-based, medications is associated with improved survival, in diabetic patients with acute coronary, syndrome - Data from TSOC ACS-DM registry
|
Chen K.-C.; Yin W.-H.; Wu C.-C.; Chan S.-H.; Wu Y.-W.; Wang K.Y.; Chang K.-C.; HWANG, JUEY-JEN; Voon W.-C.; Hsieh I.-C.; Chong J.-T.; Lin W.-S.; Hsu C.-N.; Ueng K.-C.; Hsia C.-P.; Liu J.-C.; Yeh J.-S.; Mar G.-Y.; Shih J.-Y.; Kuo J.-Y.; Tsao H.-M.; Tseng W.-K.; Yang C.-H.; Chang C.-C.; Chiang C.-E.; Lei M.-H.; Lin J.-F.; Shyu K.-G. |
臺大學術典藏 |
2022-09-16T08:49:07Z |
Cell metabolomics analyses revealed a role of altered fatty acid oxidation in neurotoxicity pattern difference between nab-paclitaxel and solvent-based paclitaxel
|
Huang J.-W.; CHING-HUA KUO; Kuo H.-C.; Shih J.-Y.; Tsai T.-W.; Chang L.-C. |
臺大學術典藏 |
2022-09-16T03:42:12Z |
Digital infarcts showing microangiopathy in adult dermatomyositis suggest severe pulmonary involvement and poor prognosis [3]
|
Tjiu J.-W.; SUNG-JAN LIN; Wang L.-F.; Shih J.-Y.; Yu C.-J.; Liang C.-W.; Chu C.-Y. |
臺大學術典藏 |
2022-09-15T01:09:03Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Chia-Chi Lin; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
臺大學術典藏 |
2022-09-15T01:08:54Z |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Chia-Chi Lin; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
臺大學術典藏 |
2022-09-15T01:08:50Z |
Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M–Positive NSCLC
|
Liao B.-C.; Hsu W.-H.; Lee J.-H.; Yang C.-Y.; Tsai T.-H.; Liao W.-Y.; Ho C.-C.; Chia-Chi Lin; Shih J.-Y.; Yu C.-J.; Soo R.A.; Yang J.C.-H. |
臺大學術典藏 |
2022-09-13T08:19:02Z |
In-hospital implementation of evidence-based, medications is associated with improved survival, in diabetic patients with acute coronary, syndrome - Data from TSOC ACS-DM registry
|
Chen K.-C.; Yin W.-H.; CHIH-CHENG WU; Chan S.-H.; Wu Y.-W.; Wang K.Y.; Chang K.-C.; Hwang J.-J.; Voon W.-C.; Hsieh I.-C.; Chong J.-T.; Lin W.-S.; Hsu C.-N.; Ueng K.-C.; Hsia C.-P.; Liu J.-C.; Yeh J.-S.; Mar G.-Y.; Shih J.-Y.; Kuo J.-Y.; Tsao H.-M.; Tseng W.-K.; Yang C.-H.; Chang C.-C.; Chiang C.-E.; Lei M.-H.; Lin J.-F.; Shyu K.-G. |
臺大學術典藏 |
2022-08-19T00:21:13Z |
Gefitinib treatment for non-small cell lung cancer - A study including patients with poor performance status
|
Shih J.-Y.; CHIUN HSU; Yang P.-C.; Su W.-P.; Yang C.-H.; Yu C.-J. |
臺大學術典藏 |
2022-08-19T00:21:10Z |
Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer
|
Yang P.-C.; Chang G.-C.; CHIUN HSU; Gow C.-H.; Yang C.-H.; Shih J.-Y.; Chen K.-C.; Yu C.-J.; Yang T.-Y.; Lin C.-P.; Su W.-P. |
臺大學術典藏 |
2022-08-19T00:21:08Z |
Predictors of toxicity of weekly docetaxel in chemotherapy-treated non-small cell lung cancers
|
Chen J.-P.; Lo Y.; Yu C.-J.; CHIUN HSU; Shih J.-Y.; Yang C.-H. |
臺大學術典藏 |
2022-08-19T00:21:07Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
CHIUN HSU; Kuo S.-H.; Hu F.-C.; Cheng A.-L.; Shih J.-Y.; Yu C.-J.; Lin C.-C.; Huang T.-C.; Yang P.-C.; Yang C.-H. |
臺大學術典藏 |
2022-08-12T06:28:17Z |
The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells
|
Su J.-L.; Yang P.-C.; Shih J.-Y.; Yang C.-Y.; Wei L.-H.; Hsieh C.-Y.; Chou C.-H.; Jeng Y.-M.; Wang M.-Y.; KING-JEN CHANG; Hung M.-C.; Kuo M.-L. |
臺大學術典藏 |
2022-08-12T06:28:09Z |
The VEGF-C/Flt-4 Axis Promotes Invasion and Metastasis of Cancer Cells (DOI:10.1016/j.ccr.2006.02.018)
|
Su J.-L.; Yang P.-C.; Shih J.-Y.; Yang C.-Y.; Wei L.-H.; Hsieh C.-Y.; Chou C.-H.; Jeng Y.-M.; Wang M.-Y.; KING-JEN CHANG; Hung M.-C.; Kuo M.-L. |
臺大學術典藏 |
2022-08-12T06:28:02Z |
The VEGF-C/Flt-4 Axis Promotes Invasion and Metastasis of Cancer Cells (DOI:10.1016/j.ccr.2006.02.018)
|
Su J.-L.; Yang P.-C.; Shih J.-Y.; Yang C.-Y.; Wei L.-H.; Hsieh C.-Y.; Chou C.-H.; Jeng Y.-M.; Wang M.-Y.; KING-JEN CHANG; Hung M.-C.; Kuo M.-L. |
臺大學術典藏 |
2022-08-10T02:37:42Z |
Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M�VPositive NSCLC
|
Liao B.-C.; Hsu W.-H.; Lee J.-H.; Yang C.-Y.; Tsai T.-H.; Liao W.-Y.; Ho C.-C.; Lin C.-C.; Shih J.-Y.; Yu C.-J.; Soo R.A.; CHIH-HSIN YANG |
臺大學術典藏 |
2022-08-10T02:37:41Z |
Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With Kras Mutation in East Asian Populations: A Single-Center Cohort Study in Taiwan
|
Wu S.-G.; Liao W.-Y.; Su K.-Y.; Yu S.-L.; Huang Y.-L.; Yu C.-J.; CHIH-HSIN YANG; Shih J.-Y. |
臺大學術典藏 |
2022-08-10T02:37:40Z |
Real-world insights into patients with advanced NSCLC and MET alterations
|
Bittoni M.; CHIH-HSIN YANG; Shih J.-Y.; Peled N.; Smit E.F.; Camidge D.R.; Arasada R.R.; Oksen D.; Boutmy E.; Stroh C.; Johne A.; Carbone D.P.; Paik P.K. |
臺大學術典藏 |
2022-06-29T02:53:22Z |
Recurrence of pericardial effusion after different procedure modalities in patients with non-small-cell lung cancer
|
Chang, L-K; Kuo, Y-W; SHANG-GIN WU; Chung, K-P; Shih, J-Y |
臺大學術典藏 |
2022-06-27T07:07:54Z |
First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer
|
Wu J.-Y.; CHONG-JEN YU; Yang C.-H.; Wu S.-G.; Chiu Y.-H.; Gow C.-H.; Chang Y.-C.; Hsu Y.-C.; Wei P.-F.; Shih J.-Y.; Yang P.-C. |
臺大學術典藏 |
2022-06-27T07:07:54Z |
Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma
|
Wu S.-G.; Gow C.-H.; CHONG-JEN YU; Chang Y.-L.; Yang C.-H.; Hsu Y.-C.; Shih J.-Y.; Lee Y.-C.; Yang P.-C. |
臺大學術典藏 |
2022-06-27T07:07:53Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Hsu C.; Kuo S.-H.; Hu F.-C.; Cheng A.-L.; Shih J.-Y.; CHONG-JEN YU; Lin C.-C.; Huang T.-C.; Yang P.-C.; Yang C.-H. |
臺大學術典藏 |
2022-06-27T07:07:53Z |
Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern
|
Wu S.-G.; Chang Y.-L.; Hsu Y.-C.; Wu J.-Y.; Yang C.-H.; CHONG-JEN YU; Tsai M.-F.; Shih J.-Y.; Yang P.-C. |
臺大學術典藏 |
2022-06-27T07:07:51Z |
Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer
|
Gow C.-H.; Chang Y.-L.; Hsu Y.-C.; Tsai M.-F.; Wu C.-T.; CHONG-JEN YU; Yang C.-H.; Lee Y.-C.; Yang P.-C.; Shih J.-Y. |
臺大學術典藏 |
2022-06-27T07:07:49Z |
EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment
|
Huang C.-L.; Yang C.-H.; Yeh K.-H.; Hu F.-C.; Chen K.-Y.; Shih J.-Y.; Lin Z.-Z.; CHONG-JEN YU; Cheng A.-L.; Yang P.-C. |
臺大學術典藏 |
2022-06-27T07:07:47Z |
Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer
|
Wu J.-Y.; Shih J.-Y.; Yang C.-H.; Chen K.-Y.; Ho C.-C.; CHONG-JEN YU; Yang P.-C. |
臺大學術典藏 |
2022-06-27T07:07:45Z |
Pemetrexed for heavily pretreated patients with advanced non-small cell lung cancer
|
Lee J.-H.; CHONG-JEN YU; Chen K.-Y.; Shih J.-Y.; Lin Y.-L.; Yang C.-H. |
臺大學術典藏 |
2022-06-27T07:07:45Z |
Octogenarians with advanced non-small cell lung cancer: Treatment modalities, survival, and prognostic factors
|
Chen K.-Y.; Chen J.-H.; Shih J.-Y.; Yang C.-H.; CHONG-JEN YU; Yang P.-C. |
臺大學術典藏 |
2022-06-27T07:07:44Z |
Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer
|
Wu J.-Y.; CHONG-JEN YU; Shih J.-Y.; Yang C.-H.; Yang P.-C. |
臺大學術典藏 |
2022-06-27T07:07:44Z |
Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptors
|
Lin C.-C.; Hsu H.-H.; Sun C.-T.; Shih J.-Y.; Lin Z.-Z.; CHONG-JEN YU; Chen G.G.; Hsin M.K.Y.; Lam K.C.; Leung L.; Yang C.-H.; Mok T. |
臺大學術典藏 |
2022-06-27T07:07:42Z |
Use of cetuximab after failure of gefitinib in patients with advanced non-small-cell lung cancer
|
Wu J.-Y.; Yang C.-H.; Hsu Y.-C.; CHONG-JEN YU; Chang S.-H.; Shih J.-Y.; Yang P.-C. |
臺大學術典藏 |
2022-06-27T07:07:40Z |
Favorable response to gefitinib treatment of lung adenocarcinoma with coexisting germline and somatic epidermal growth factor receptor mutations
|
Chung K.-P.; Shih J.-Y.; CHONG-JEN YU |
臺大學術典藏 |
2022-06-27T07:07:39Z |
Epidermal growth factor receptor mutations in small cell lung cancer: A brief report
|
Shiao T.-H.; Chang Y.-L.; CHONG-JEN YU; Chang Y.-C.; Hsu Y.-C.; Chang S.-H.; Shih J.-Y.; Yang P.-C. |
臺大學術典藏 |
2022-06-27T07:07:39Z |
The prognostic value of the simplified comorbidity score in the treatment of small cell lung carcinoma
|
Kuo Y.-W.; Jerng J.-S.; Shih J.-Y.; Chen K.-Y.; CHONG-JEN YU; Yang P.-C. |
臺大學術典藏 |
2022-06-27T07:07:36Z |
Gefitinib therapy in patients with advanced non-small cell lung cancer with or without testing for epidermal growth factor receptor (EGFR) mutations
|
Wu J.-Y.; Shih J.-Y.; Chen K.-Y.; Yang C.-H.; CHONG-JEN YU; Yang P.-C. |
臺大學術典藏 |
2022-06-27T07:07:35Z |
Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer
|
Wu J.-Y.; CHONG-JEN YU; Chang Y.-C.; Yang C.-H.; Shih J.-Y.; Yang P.-C. |
臺大學術典藏 |
2022-06-27T07:07:35Z |
Good response to pemetrexed in patients of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations
|
Wu S.-G.; Yang C.-H.; CHONG-JEN YU; Lee J.-H.; Hsu Y.-C.; Chang Y.-L.; Shih J.-Y.; Yang P.-C. |
臺大學術典藏 |
2022-06-27T07:07:32Z |
Including total EGFR staining in scoring improves EGFR mutations detection by mutation-specific antibodies and EGFR TKIs response prediction
|
Wu S.-G.; Chang Y.-L.; Lin J.-W.; Wu C.-T.; Chen H.-Y.; Tsai M.-F.; Lee Y.-C.; CHONG-JEN YU; Shih J.-Y. |
臺大學術典藏 |
2022-06-27T07:07:31Z |
Clustered genomic alterations in chromosome 7p dictate outcomes and targeted treatment responses of lung adenocarcinoma with EGFR-activating mutations
|
Yuan S.; Yu S.-L.; Chen H.-Y.; Hsu Y.-C.; Su K.-Y.; Chen H.-W.; Chen C.-Y.; CHONG-JEN YU; Shih J.-Y.; Chang Y.-L.; Cheng C.-L.; Hsu C.-P.; Hsia J.-Y.; Lin C.-Y.; Wu G.; Liu C.-H.; Wang C.-D.; Yang K.-C.; Chen Y.-W.; Lai Y.-L.; Hsu C.-C.; Lin T.-C.; Yang T.-Y.; Chen K.-C.; Hsu K.-H.; Chen J.J.W.; Chang G.-C.; Li K.-C.; Yang P.-C. |
臺大學術典藏 |
2022-06-27T07:07:31Z |
Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: The association with treatment efficacy of pemetrexed
|
Chen C.-Y.; Chang Y.-L.; Shih J.-Y.; Lin J.-W.; Chen K.-Y.; Yang C.-H.; CHONG-JEN YU; Yang P.-C. |
臺大學術典藏 |
2022-06-27T07:07:28Z |
Percutaneous computed tomography-guided coaxial core biopsy for small pulmonary lesions with ground-glass attenuation
|
Lu C.-H.; Hsiao C.-H.; Chang Y.-C.; Lee J.-M.; Shih J.-Y.; Wu L.-A.; CHONG-JEN YU; Liu H.-M.; Shih T.T.-F.; Yang P.-C. |
臺大學術典藏 |
2022-06-27T07:07:28Z |
EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with Wild-type EGFR
|
Wu S.-G.; Kuo Y.-W.; Chang Y.-L.; Shih J.-Y.; Chen Y.-H.; Tsai M.-F.; CHONG-JEN YU; Yang C.-H.; Yang P.-C. |
臺大學術典藏 |
2022-06-27T07:07:27Z |
Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum
|
Liao W.-Y.; Shih J.-Y.; Chang G.-C.; Cheng Y.-K.; Yang J.C.-H.; Chen Y.-M.; CHONG-JEN YU |
臺大學術典藏 |
2022-06-27T07:07:27Z |
Effusion immunocytochemistry as an alternative approach for the selection of first-line targeted therapy in advanced lung adenocarcinoma
|
Tsai T.-H.; Wu S.-G.; Chang Y.-L.; Wu C.-T.; Tsai M.-F.; Wei P.-F.; Yang C.-H.; CHONG-JEN YU; Yang P.-C.; Shih J.-Y. |
臺大學術典藏 |
2022-06-27T07:07:26Z |
Clinical significance of thyroid transcription factor-1 in advanced lung adenocarcinoma under epidermal growth factor receptor tyrosine kinase inhibitor treatment
|
Chung K.-P.; Huang Y.-T.; Chang Y.-L.; CHONG-JEN YU; Yang C.-H.; Chang Y.-C.; Shih J.-Y.; Yang P.-C. |
臺大學術典藏 |
2022-06-27T07:06:54Z |
Elevated serum levels of mucin-associated antigen in patients with acute respiratory distress syndrome
|
Shih J.-Y.; Yang S.-C.; CHONG-JEN YU; Wu H.-D.; Liaw Y.-S.; Wu R.; Yang P.-C. |